IP Library Granted Patent US 10,844,358
Granted Patent B2
US 10,844,358 · App. 16/196,205 · Granted Nov 24, 2020

Polynucleotides encoding biocatalysts and methods for hydroxylation of chemical compounds

Inventors: Jovana Nazor (Milpitas, CA); Robert Osborne (Raleigh, NC); Jack Liang (San Mateo, CA); Jonathan Vroom (South San Francisco, CA); Xiyun Zhang (Fremont, CA); David Entwistle (San Carlos, CA); Rama Voladri (Milpitas, CA); Ravi David Garcia (Los Gatos, CA); Jeffrey C. Moore (Westfield, NJ); Shane Grosser (Princeton, NJ); Birgit Kosjek (Westfield, NJ); Matthew Truppo (Ocean Township, NJ)
Assignee: Codexis, Inc.
C12N9/0071C12P17/12C12Y114/11C12Y114/11002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,844,358
App. No.
16/196,205
Granted
Nov 24, 2020
Kind
B2
Abstract

The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Claims (16)

1. An engineered polynucleotide encoding an engineered polypeptide having proline hydroxylase activity comprises an amino acid sequence having at least 95% or more sequence identity to reference sequence SEQ ID NO:810 and one or more residue differences as compared to SEQ ID NO: 810 at residue positions selected from: 2, 4, 8, 10, 15, 26, 30, 33, 36, 37, 39, 42, 43, 44, 45, 48, 50, 52, 55, 56, 57, 58, 61, 62, 63, 71, 76, 77, 81, 82, 87, 88, 92, 94, 95, 97, 98, 101, 107, 109, 114, 115, 119, 121, 124, 128, 130, 131, 132, 134, 136, 145, 151, 153, 156, 158, 160, 161, 165, 166, 168, 173, 176, 178, 180, 184, 194, 213, 230, 237, 240, 256, 263, 266, 269, 270, 271, 273, 274, 275, and 280.

2. The engineered polynucleotide encoding an engineered polypeptide having proline hydroxylase activity of claim 1 , wherein said one or more residue differences as compared to SEQ ID NO:810 is at residue positions selected from: 33, 40, 95, 156, and 166.

3. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein said engineered polypeptide is capable of converting (S)-pipecolic acid to (2S,5S)-5-hydroxypipecolic acid.

4. The engineered polynucleotide encoding an engineered polypeptide of claim 3 , wherein said engineered polypeptide is capable of converting (S)-pipecolic acid to (2S,5S)-5-hydroxypipecolic acid with at least 1.2 fold, 1.5 fold, 2 fold, 3 fold, 4 fold, 5 fold, 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, 100 fold or more enzymatic activity of the naturally occurring enzyme.

5. The engineered polynucleotide encoding an engineered polypeptide of claim 3 , wherein said engineered polypeptide is capable of converting (S)-pipecolic acid to (2S,5S)-5-hydroxypipecolic acid with greater than 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more diastereomeric excess of (2S,5R)-5-hydroxypipecolic acid.

6. The engineered polynucleotide of claim 1 , wherein said polynucleotide comprises a nucleic acid sequence optimized for expression in E. coli.

7. The engineered polynucleotide of claim 1 , wherein said polynucleotide comprises SEQ ID NO: 809.

8. The engineered polynucleotide of claim 3 , wherein said polynucleotide comprises a nucleic acid sequence optimized for expression in E. coli.

9. The polynucleotide of claim 2 , wherein said polynucleotide comprises a nucleic acid sequence optimized for expression in E. coli.

10. An expression vector comprising the polynucleotide of claim 1 , optionally further comprising at least one control sequence.

11. The expression vector of claim 10 , wherein said vector comprises SEQ ID NO:1007, 1008, or 1009.

12. A host cell comprising the polynucleotide of claim 1 .

13. A host cell comprising the expression vector of claim 10 .

14. The host cell of claim 13 , wherein the host cell is E. coli.

15. A method of preparing an engineered polypeptide, comprising culturing the host cell of claim 12 , under conditions suitable for expression of the polypeptide.

16. The method of claim 15 , further comprising a step of isolating the engineered polypeptide.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (3)
Division 15491692 · Apr 19, 2017
Provisional Application 62347724 · Jun 9, 2016
Related Publication 20190078061A1 · Mar 14, 2019
Cited By (1)
US 12,286,648